Company
About Biosynth
Biosynth (former EUCODIS Bioscience)
Biosynth delivers high-performance enzyme solutions for applications in pharma, biotech, fine chemicals, food & feed, and cosmetics industries. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes Biosynth has a proven track record of providing customized solutions. As an application-driven provider of tailored enzyme solutions, we work closely with our customers to better understand and fulfill their individual biocatalyst needs.
Biosynth is an expert in engineering and developing enzymes for industrial applications, using our proprietary in vivo recombination technology – either alone or in combination with other mutagenesis technologies – to modulate activities of target enzymes in accordance with required specifications. Coupled with high-throughput screening capabilities and assay platforms, we can deliver optimized enzymes with desired properties within agreed timelines.
Our contract manufacturing capabilities for recombinant protein and enzyme production cover the whole spectrum of custom protein & enzyme services like protein & enzyme engineering, strain & bioprocess development, fermentation in various pro- and eukaryotic host expression systems, DSP & protein purification and routine industrial protein manufacturing. Biosynth is specialized in setting up optimized bioprocesses for the scale-up and manufacture of recombinant proteins under ISO 9001:2015 to assure maximum yields, stability and desired purity in reproducible and reliable quality.
Biosynth was founded in 2007 (as EUCODIS Bioscience) and is headquartered in Vienna, Austria.
MANAGEMENT TEAM
The Biosynth GmbH Management Team
Our management has extensive experience in the biotechnology and pharma industry with special expertise in industrial enzyme development and marketing. With both scientific and business related backgrounds our team can find customized solutions in order to fulfill our customers’ needs.
Dr. Jan Modregger, MBA
CEO AND Head of Research & Development, Production
Jan Modregger was appointed as CEO of Biosynth (former EUCODIS Bioscience) in October 2021, after serving the company as Head of Research and Development since 2011 and Project Head for various enzyme development projects since 2008.
Before joining Biosynth (former EUCODIS Bioscience), he worked as research group leader in the pharmaceutical biotech industry responsible for several development projects involving anti-inflammatory diseases.
Jan Modregger holds a PhD in Physiological Chemistry from the University of Cologne, Germany and worked as a research associate at the Howard Hughes Medical Institute at Yale University, New Haven. In 2010, he received a fellowship for the executive MBA program of the Institute for Management, Salzburg, and the University of Klagenfurt, which he completed successfully in 2013.
Mag. Michael Zimmel
Head of Finance & Administration
Michael Zimmel was appointed as Head of Finance & Administration in 2017 after supporting Biosynth as Finance Specialist since 2015.
As Head of Finance & Administration he is providing Biosynth with more than 15 years of experience in finance management with a specific emphasis on financial and business controlling, funding of investment projects (including subsidies/grants), purchasing, accounting and taxes as well as auditing. He worked in several sectors with unique requirements like the pharmaceutical, energy, agrochemical, functional food- and biotech industry.
Michael Zimmel holds a Master degree in Business Administration from the Vienna University of Economics and Business, Austria.
Karim Vadiwala, PhD
Business Development & SALES MANAGER
Karim Vadiwala was appointed as Business Development and Sales Manager in February 2021.
He has finished Social Intrapreneurship for Innovation in Health course by Boehringer Ingelheim and Ashoka. He has also undertaken ‘From Scientist to Entrepreneur’ course by INiTS, Vienna’s High-Tech Incubator, and Leadership Management course by hfp consulting, Germany. He also has business experience in life science and digital start-ups.
Karim Vadiwala holds a PhD in Molecular Biology from the University of Vienna and Masters in Prenatal Genetics and Fetal Medicine from University College London (UCL), London.
Karim Vadiwala is responsible for all sales and business development related activities for international customers.
Janna Frömbling, MSc
Business Development & SALES MANAGER
Janna Frömbling was appointed as Business Development and Sales Manager in 2021 after supporting EUCODIS as a Sales Associate in the past.
During her occupation at the University for Veterinary Medicine of Vienna she fostered her background in microbiology, proteomics and metabolomics. In the postion as a Sales Consultant she developed expertise in customer services and acqusition. At EUCODIS Janna Frömbling is responsible for sales, business partnering in the DACH region and marketing.
Janna Frömbling holds a MSc degree in Bioscience from the University of Münster, Germany.
Quality Management
At Biosynth (former EUCODIS Bioscience) we follow a strict quality policy which reflects the principles of the quality management system according to ISO9001:2015.
Since our customers are our highest priority, we aim to understand their requirements and surpass their expectations. We commit ourselves to best efforts to achieve our customers’ trust and confidence in our skills and strengths of tailored solutions and products to build up long-term and sustainable relationships.
We recognize ISO9001:2015 as the fundamental Quality Management system in all departments of Biosynth (former EUCODIS Bioscience), and monitor, plan and implement all measures relevant for such product quality and safety. This includes defining requirements and actions, monitoring development, production and quality control as well as considering risks and opportunities, up to managing and communicating product and process relevant changes.
RELATED DOWNLOADS
ISO9001:2015 certificate
Quality Policy
FIND OUT MORE
Our QM Manual is available on request. Please contact
vie.office(at)biosynth.com >
Business Development
Partnering
We are interested in
- Co-developing novel enzyme solutions with academic and industrial partners
- Out-licensing of our CTAT technology for bioconjugation of proteins/antibodies
- Purchasing or in-licensing of selected enzymes
- Technologies for enzyme or protein development and production that complement our core competences, both from academic institutions as well as from the industry.
We are also offering co-marketing opportunities of enzymes or technologies through our experienced marketing and sales team.
FIND OUT MORE
For more information or to submit your inquiry please contact us at
vie.orders(at)biosynth.com >
Partners
Biosynth GmbH has an extensive network of consultants and partners to expand and complement our capabilities and offers a highly competitive service and product portfolio to our customers.
Our partners include:
Investors
EUCODIS is now part of the Biosynth group. For more information also view www.biosynth.com.
Additionally, the Company has received significant support by the following Austrian and German public agencies:
Career
Our employees are constantly given the opportunity of meeting new and intriguing challenges in order to find innovative solutions to our customers’ requests, which are as varied as the application fields of our enzymes.
Open positions:
(Biosynth - former Eucodis - is using your personal data exclusively for business-relevant communication. We ensure that all your personal data are not passed onto third parties. If you have any questions please do not hesitate to contact us via email at vie.office(at)biosynth.com.)